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DNA replication across blocking lesions occurs by transle-
sion DNA synthesis (TLS), involving a multitude of
mutagenic DNA polymerases that operate to protect the
mammalian genome. Using a quantitative TLS assay, we
identified three main classes of TLS in human cells: two
rapid and error-free, and the third slow and error-prone.
A single gene, REV3L, encoding the catalytic subunit of
DNA polymerase f (polf), was found to have a pivotal role
in TLS, being involved in TLS across all lesions examined,
except for a TT cyclobutane dimer. Genetic epistasis siRNA
analysis indicated that discrete two-polymerase combina-
tions with polf dictate error-prone or error-free TLS across
the same lesion. These results highlight the central role of
polf in both error-prone and error-free TLS in mammalian
cells, and show that bypass of a single lesion may involve
at least three different DNA polymerases, operating in
different two-polymerase combinations.
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Introduction
Despite the existence of efficient DNA repair mechanisms,
DNA replication encounters unrepaired lesions, which may
lead to arrested progression of replication forks and the
formation of replication gaps (Rupp and Howard-Flanders,
1968; Lehmann, 1972; Meneghini, 1976; Friedberg et al,
2006; Lehmann and Fuchs, 2006; Lopes et al, 2006; Mojas
et al, 2007). Translesion DNA synthesis (TLS) is a ubiquitous
error-prone response to arrested replication forks and gaps,
which is conserved from Escherichia coli to humans. TLS is
mediated by specialized DNA polymerases that are character-
ized by low fidelity and an ability to replicate across certain
types of damaged sites in template DNA. Such replication can
be accurate with respect to the nucleotide composition of the
damaged template, or inaccurate, leading to the generation of
mutations (Livneh, 2001; Goodman, 2002; Prakash and
Prakash, 2002; Lehmann et al, 2007).
TLS in E. coli involves a single major DNA polymerase,
DNA polymerase V, (Reuven et al, 1999; Tang et al, 1999),
functioning in error-prone TLS across a diversity of DNA
lesions (Reuven et al, 1999; Tang et al, 1999, 2000; Maor-
Shoshani et al, 2003). E. coli also contains DNA polymerases
II and IV, which bypass lesions under specific situations
(Napolitano et al, 2000; Jarosz et al, 2006). In
Saccharomyces cerevisiae, two genetically distinct TLS path-
ways have been defined by the DNA polymerases involved. A
polZ (RAD30)-dependent pathway performs TLS across a TT
CPD (thymine-thymine cyclobutane pyrimidine dimer) with
high fidelity (Johnson et al, 1999b), and a polz (REV3 and
REV7)-dependent pathway functions in error-prone TLS across
UV-induced lesions (Nelson et al, 1996a, b; Lawrence, 2002;
Gibbs et al, 2005), and other damages (Xie et al, 2003;
Zhao et al, 2006). A key regulatory element in TLS is PCNA,
the monoubiquitination of which signals the switch from
high-fidelity replication to TLS (Hoege et al, 2002; Stelter
and Ulrich, 2003).
The situation in mammalian cells is more complicated, due
to the presence of many more low-fidelity DNA polymerases
than in E. coli or S. cerevisiae: four specialized Y-family DNA
polymerases (compared with two in E. coli and S. cerevisiae),
and six additional low-fidelity polymerases that belong to
other DNA polymerase families (Hubscher et al, 2000;
Goodman, 2002). As in yeast, the monoubiquitination of
PCNA appears to have an important regulatory function
(Kannouche et al, 2004; Watanabe et al, 2004; Bienko et al,
2005; Bi et al, 2006). Moreover, both monoubiquitination of
PCNA, and the efficiency and accuracy of TLS are regulated
by the p53-inducible protein p21 (Avkin et al, 2006; Soria
et al, 2006) through its interaction with PCNA (Avkin et al,
2006). However, many mechanistic aspects of TLS are still
unknown. In the present study, we used kinetics and genetic
analysis of TLS based on gene knockout or knockdown, in
conjunction with gapped plasmids carrying single site-speci-
fic lesions to decipher some of the operation principles of TLS
in mammalian cells. Our results indicate that there exist at
least three major pathways of TLS in mammalian cells, and
that a single polymerase, DNA polymerase z (polz), has a
Received: 30 August 2008; accepted: 2 December 2008; published
online: 15 January 2009
*Corresponding author. Department of Biological Chemistry,
The Weizmann Institute of Science, Hertzl Street, Rehovot 76100, Israel.
Tel.: þ 972 8 934 3203; Fax: þ 972 8 934 4169;
E-mail: zvi.livneh@weizmann.ac.il
The EMBO Journal (2009) 28, 383–393 | & 2009 European Molecular Biology Organization | All Rights Reserved 0261-4189/09
www.embojournal.org







pivotal and irreplaceable role in TLS across a wide variety of
DNA lesions in mammalian cells. It functions in both error-
free and error-prone TLS, and cooperates with other DNA
polymerases in two-polymerase mechanisms. These results
highlight the crucial function polz has in TLS, and provide the
first evidence for a two-polymerase mechanism in living
mammalian cells.
Results
TLS exhibits distinct classes of kinetics and accuracy
in human cells
In this study, we utilized a quantitative TLS assay system
based on gapped plasmids carrying site-specific DNA lesions
in the single-stranded region opposite to the gap (gap-lesion
plasmid) (Avkin et al, 2002, 2004; Adar and Livneh, 2006)
(Supplementary Figure 1s). Briefly, cultured cells were trans-
fected with a plasmid mixture comprising a gap-lesion plas-
mid with a site-specific lesion opposite a gap and a kanR
marker, a control gapped plasmid without a lesion (cmR), and
an intact carrier plasmid (ampR). After allowing time for TLS-
dependent gap filling, plasmids were extracted from the cells
using alkaline conditions, such that only fully repaired plas-
mids remain covalently closed, and those were used to
transform an E. coli recA indicator strain, which is defective
in TLS. The bacterial cells were plated in parallel on kan-LB
plates to select for repaired gap-lesion plasmids, and on cm-
LB plates to select for the control plasmid. The extent of TLS
was determined from the ratio of kanR/cmR E. coli colonies.
To determine the fidelity of TLS, plasmids were extracted
from individual kanR colonies and subjected to DNA se-
quence analysis across the region corresponding to the gap.
We demonstrated earlier that this assay system reflects TLS
events occurring in the mammalian cell (Avkin et al, 2002), is
responsive to the cellular composition of DNA polymerases in
a way similar to chromosomal TLS (Avkin et al, 2004; Hendel
et al, 2008), and subject to regulation by p53 and p21 through
PCNA ubiquitination (Avkin et al, 2006). The plasmids
become chromatinized in the cells (data not shown), and
may better reflect TLS events occurring at post-replication
gaps, rather than replication forks (e.g. behind the fork;
Niimi et al, 2008).
Using the gapped plasmid assay system, we measured the
time course of TLS across six diverse, site-specific lesions, to
obtain a general view on the kinetics of TLS. The lesions
included benzo[a]pyrene-guanine (BP-G; (þ )–trans-BPDE-
N2-G adduct), a major tobacco smoke-induced DNA lesion;
cisplatin-GG (cisPt-GG), an intra-strand adduct formed in
DNA by the cancer chemotherapy drug cisplatin; a furanyl
AP (apurinic/apyrimidinic (abasic)) site, which is a synthetic
analogue of the native AP site generated in DNA by sponta-
neous hydrolysis; 4-hydroxyequilenin-C (4-OHEN-C), an ad-
duct formed in DNA by metabolites of equilin and equilenin,
which are widely used in oestrogen replacement therapy; and
TT CPD and thymine-thymine 6-4 photoproduct (TT 6-4 PP),
the two main UV-induced DNA lesions. As can be seen in
Figure 1 (and Supplementary Tables 1s–6s), the six time
course curves fell into three kinetically distinct groups. TLS
across the TT CPD was very rapid, and highly efficient,
reaching nearly 40% bypass after 1 h, and over 85% after
8 h (Figure 1; Supplementary Table 1s). TLS across the BP-G
and cisPt-GG adducts exhibited an initial lag of 1–2 h, after
which it proceeded at a fast pace, reaching B40% bypass
after two additional hours, and B60% at 8 h after the lag
(Figure 1; Supplementary Tables 2s and 3s). TLS across
TT 6-4 PP, the AP site and 4-OHEN-C was slow and relatively
inefficient, reaching 14–27% bypass after 24 h (Figure 1;
Supplementary Tables 4s–6s). These results are quite remark-
able, given that the lesions that share similar kinetics are
chemically very different, and have no obvious structural,
conformational, or chemical commonalities.
The fidelity of TLS across each lesion was determined using
DNA sequence analysis. As can be seen in Figure 2A–F (and
Supplementary Tables 7s–12s), each lesion exhibited a
unique mutational signature, consistent with previous results
(Friedberg et al, 2006), except for 4-OHEN-C, for which no
previous mammalian in vivo mutational data existed. TT CPD,
BP-G, and cisPt-GG were bypassed accurately in approximately
90% of the TLS events (error frequency of approximately 10%;
Figure 2A–C; Supplementary Tables 7s–9s). In contrast, TLS
across TT 6-4 PP and 4-OHEN-C was highly mutagenic with
error frequencies in the range of 71–75% (Figure 2D and E;
Supplementary Tables 10s and 11s). Most of the mutations
occurred opposite the damaged template bases; however, for
TT CPD, TT 6-4 PP, and 4-OHEN-C, a significant fraction of the
mutations were semitargeted to the two nearest bases flanking
the lesion (Figure 2A–F; Supplementary Tables 7s–12s). The
mutagenicity of TLS across an AP site cannot be defined in the
absence of knowledge of the missing base. However, as sponta-
neous depurination is much faster than depyrimidination, most
AP sites generated are at purines. Therefore, any insertion of a
purine nucleotide opposite the AP site can be considered
functionally mutagenic, providing a minimal estimate of its
mutagenicity during TLS. Interestingly, the fidelity of bypass
correlated with its speed and efficiency: The rapid and efficient
TLS across TT-CPD, BP-G, and cisPt-GG was accurate, whereas
the slow and inefficient TLS across TT 6-4 PP, 4-OHEN-C and an
AP site was highly mutagenic (Figure 2G–I).
Polf is involved in both error-free and error-prone TLS
If the kinetically distinct branches of TLS represent
distinct pathways, they should exhibit characteristic genetic
requirements, particularly of TLS DNA polymerase genes. For
Figure 1 Kinetics of TLS across six different types of DNA damage
in human U2OS cells. Plasmid mixtures containing the indicated
gap-lesion plasmid, along with the control and the carrier plasmids,
were introduced into human U2OS cells. Following incubation of
0–24 h to allow TLS, the DNA was extracted and used to transform
an E. coli indicator strain. The extent of TLS was calculated as
described under Materials and methods. Each of the data represents
the average of four TLS experiments. The detailed data are pre-
sented in Supplementary Tables 1s–6s.
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the three lesions that were bypassed by rapid and accurate
TLS, there is evidence for the involvement of specific DNA
polymerases: polZ for TLS across TT CPD and cisPt-GG, and
polk for TLS across BP-G. This is based on in vivo studies
(Maher et al, 1976; Ogi et al, 2002; Bassett et al, 2004), in
vitro results with purified DNA polymerases (Johnson et al,
1999a; Masutani et al, 1999, 2000; Ohashi et al, 2000;
Vaisman et al, 2000), as well as studies from our lab using
the gap-lesion plasmid assay utilized here (Avkin et al, 2004;
Hendel et al, 2008) (and see below). As for the lesions in the
slow and mutagenic branch of TLS, based on studies in
S. cerevisiae (Haracska et al, 2001; Gibbs et al, 2005) and
human cells (Gibbs et al, 1998) we suspected that their bypass
involves polz. We therefore analysed TLS across these three
lesions in Rev3Lþ /þand Rev3L/ (the mouse homologue of
the yeast REV3 gene, encoding the catalytic subunit of DNA
polymerase z) mouse embryonic fibroblasts, using the gap-
lesion plasmid assay system. As controls, we examined TLS
across the three lesions bypassed by the rapid and accurate
branches of TLS. In addition, we examined TLS across an
artificial lesion in the form of a chain of 12 methylenes inserted
into the DNA backbone (M12; Adar and Livneh, 2006).
As can be seen in Figure 3A and Supplementary Table 13s,
for all lesions except the TT CPD, TLS was significantly
reduced in Rev3L/ cells, compared with Rev3Lþ /þ cells.
This reduction was 7.3-fold for the BP-G adduct, 3.5-fold for
the cisPt-GG adduct, 2-fold for the AP site, 2.8-fold for the
4-OHEN-C lesion, 5.3-fold for the TT 6-4 PP, and 7.8-fold for the
M12 lesion (Figure 3A; Supplementary Table 13s). Thus, polz
appears to be involved not only in TLS across lesions
classified as being bypassed via the slow and mutagenic
pathway but also across lesions bypassed by rapid and
accurate TLS, except for TT CPD.
The extent of TLS across several lesions in the mouse cells
(Figure 3) was quantitatively different from that obtained in
the human cells (Figure 1). This may stem from the difference
in organisms and cell types, and the fact that the mice cells
were p53 null, a situation under which TLS is deregulated
(Avkin et al, 2006). Therefore, to examine whether REV3L is
similarly involved in TLS in the human cell line U2OS used in
the kinetics analysis (which has a wild-type p53), we ana-
lysed TLS across several lesions in U2OS cells in which the
expression of REV3L was knocked down using siRNA. As can
be seen in Figure 3C, transfection of U2OS cells with REV3L
siRNA caused a strong reduction in REV3L mRNA expression,
whereas the control siRNA had essentially no effect. We then
assayed TLS across four different lesions. As can be seen in
Figure 3D and Supplementary Table 21s, when REV3L was
knocked down, TLS across TT 6-4 PP, cisPt-GG, and BP-G
was decreased compared with the control siRNA. In contrast,
TLS across the TT CPD was similar. Thus, similar to the MEF,
polz is involved in TLS in the human cell line U2OS across
lesions classified as being bypassed via the slow and muta-
genic pathway, as well as the rapid and accurate pathway,
with the exception of TT CPD.
Residual TLS in the absence of polf in murine cells
is more accurate
To determine the sequence changes at the lesion caused by
the absence of Rev3L, DNA sequence was analysed in des-
cendants of gap-lesion plasmids that were repaired in Rev3L-
proficient or Rev3L-deficient cells. As shown in Figure 3B and
Supplementary Table 14s, in Rev3Lþ /þ MEF 62% of TLS
events across BP-G were error-free, involving the incorpora-
tion of dCMP, consistent with previous results (Avkin et al,
2004). In total, 37% of the TLS events across BP-G were
mutagenic, involving insertion of mainly dAMP and dTMP
opposite the lesion, although G was also misinserted
(Supplementary Table 14s). The major effect in Rev3L/
MEF was, of course, the strong decrease in TLS, as shown
in Figure 3A. DNA sequence analysis of plasmids that were
repaired in the Rev3L/ MEFs showed that a substantial
fraction contained large deletions and insertions, indicative of
the formation of DSB (27%; Supplementary Table 14s). The
Figure 2 Mutagenicity of TLS across six different types of DNA
damage in human U2OS cells. Individual colonies from the TLS
reactions presented in Figure 1 were picked, and their plasmid
content was analysed for mutations in the DNA region correspond-
ing to the original site of the lesion. The cumulative height of each
column represents the misinsertion frequency opposite the corre-
sponding lesion, whereas the coloured column sections represent
specific mutational events, colour coded as shown underneath. The
DNA sequence with the damaged bases (marked by stars) is shown
in the 50-30 direction. The detailed DNA sequence data are
presented in Supplementary Tables 7s–12s. Results are presented
for mutations formed at TT CPD (A), BP-G (B), cisPt-GG (C), TT 6-4
PP (D), 4-OHEN-C (E), and AP site (F). (G) TLS rates, calculated for
the linear TLS phase of each lesion from the data presented in
Figure 1, namely 0–2 h for TT CPD, TT 6-4 PP, 4-OHEN-C and the AP
site, and 2–4 h for BP-G and cisP-GG, are shown. (H) Maximal
values of TLS for the six lesions measured at 24 h are shown. The
data were taken from Figure 1 and Supplementary Tables 1s–6s.
(I) Mutagenic TLS out of total TLS events. For the AP site, insertion
of A or G was taken as a mutagenic event. The data were taken
from Figures 1 and 2, and Supplementary Tables 1s–12s.
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absolute frequency of these events was similar in Rev3L/
and Rev3Lþ /þ MEFs, indicating that they were unrelated to
polz. Interestingly, residual TLS was more accurate in the
absence of Rev3L than in its presence, with only 5.9%
mutagenic TLS events. Thus, residual TLS in the absence of
Rev3L was very low, but 6.3-fold less mutagenic (P¼ 0.0006;
Figure 3B; Supplementary Table 14s).
A similar effect was observed for cisPt-GG adduct
(Figure 3B; Supplementary Table 15s): although 13% of
the TLS events in Rev3Lþ /þ cells were error-prone, that is,
nucleotides other than CC were inserted opposite cisPt-GG
lesions (Supplementary Table 15s), remarkably, all 54
plasmids isolated from Rev3L/ cells contained the correct
sequence (CC) opposite cisPt-GG adducts (Figure 3B;
Supplementary Table 15s). This reflects a misinsertion fre-
quency of o1.8% (o1/54 events), indicating that TLS across
a cisPt-GG adduct is at least 7.2-fold less mutagenic in the
absence of Rev3L (P¼ 0.0062).
Similar phenomena were observed for 4-OHEN-C
(Figure 3B; Supplementary Table 16s) where TLS was 3.5-
fold less mutagenic in Rev3L/ cells compared with Rev3Lþ /þ
cells (P¼ 0.0002), and for TT 6-4 PP, where TLS was 20-fold
less mutagenic in Rev3L/ cells compared with Rev3Lþ /þ
cells (Po0.0001) (Figure 3B; Supplementary Table 17s). TLS
across TT CPD was accurate in both Rev3Lþ /þ and Rev3L/
(Figure 3B; Supplementary Table 18s) similar to the situation
in the human cells (Figure 2A; Supplementary Table 7s).
We also examined insertion specificity across an AP site
Figure 3 Involvement of Rev3L in TLS in mammalian cells. (A) The TLS assay was performed with Rev3Lþ /þ or Rev3L/ MEFs. Cells were
assayed for TLS as described under Materials and methods, using the indicated gap-lesion plasmids. Average results of at least four experiments
are presented. The detailed data are presented in Supplementary Table 13s. (B) Mutagenicity of the TLS reaction across different lesions in MEF
Rev3Lþ /þ and Rev3L/ cells. Colonies obtained in the experiments described in (A) were picked, their plasmid contents extracted, and
subjected to DNA sequence analysis. The graph shows the percentage of incorrect nucleotides inserted opposite each of the lesions. The
statistical significance of the differences in mutagenicity between the two cell types was calculated by the w2 test, yielding the following
P-values: BP-G, 0.0006; cisPt-GG, 0.006; M12, o0.0001; 4-OHEN-C, 0.0002; TT 6-4 PP, o0.0001. The detailed data are presented in
Supplementary Tables 14s–18s. (C) RT–PCR of RNA extracted from human U2OS cells transiently transfected with siRNA for REV3L. (D)
Extent of TLS in U2OS cells in which REV3L expression was knocked down using specific siRNA. Cells were assayed for TLS as described under
Materials and methods, using the indicated gap-lesion plasmids. Average results of at least four experiments are presented. The detailed data
are presented in Supplementary Table 21s.
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and an M12 insert. Regardless of the status of the Rev3L gene
most bypass events led to the incorporation of A opposite the
AP site, in agreement with previous results (Figure 2;
Supplementary Table 19s; Avkin et al, 2002). For the M12
lesion, which represents a severe type of damage, the most
pronounced effect was an increase in large deletions of
the lesion area in Rev3L/ cells (89%) compared with
Rev3Lþ /þ cells (38%), indicative of DSB formation followed
by NHEJ, possibly due to a difficulty to bypass the lesion
(Supplementary Table 20s).
When the mutational spectra were examined in the human
cell line U2OS under conditions in which expression of
REV3L was knocked down, there was essentially no differ-
ence in the accuracy of TLS compared with the control cells
(Table I). This may be due to an inherently more accurate TLS
in human cells compared with mouse cells, which remained
essentially unchanged even when expression of REV3L was
knocked down, and TLS inhibited. For example, TLS across
BP-G is less accurate in mice cells compared with human cells
(Avkin et al, 2004; Table I; Supplementary Table 14s).
Polf cooperates with polj in error-free TLS across BP-G
in human cells
As described above, due to the known role of polk in TLS
across BP-G, the strong dependence on REV3L of TLS across
this lesion was unexpected. We therefore decided to further
study TLS across this lesion. A possible explanation for these
findings was that both polk and REV3L are involved, perhaps
in a two-polymerase pathway (Johnson et al, 2000a). To
examine this possibility, we took a gene-knockdown epistasis
analysis approach, and assayed TLS in U2OS cells in which
the expression of POLK, REV3L, or both was knocked down.
As can be seen in Figure 4C, the POLK, POLH, and REV3L
siRNAs each specifically knocked down the expression of its
target polymerase by approximately 80–90%. Figure 4A and
Supplementary Table 22s present the results of TLS across
BP-G under these conditions. Knocking down the expression
of POLK caused a 2.3-fold decrease in TLS, indicating that at
least 57% of the BP-G adducts required POLK for bypass.
Knocking down the expression of REV3L caused a stronger
5.5-fold decrease in TLS, indicating that at least 82% of the
BP-G adducts required REV3L for bypass. When the expres-
sion of both POLK and REV3L was knocked down, TLS was
essentially identical to its value in cells where only REV3L
was knocked down (Figure 4A; Supplementary Table 22s). To
examine whether the combination of any two polymerases
would drastically affect TLS across BP-G, we assayed cells in
which both POLK and POLH were knocked down. TLS across
BP-G in cells in which POLH was knocked down was margin-
ally decreased, whereas when both POLH and POLK were
knocked down, TLS was similar to that observed in POLK-
knocked-down cells, indicating that polZ does not have a
major role in the extent of TLS across BP-G (Figure 4A;
Supplementary Table 22s). If at least 82% of the BP-G adducts
Table I DNA sequence analysis of TLS events across BP-G and cisPt-GG in human U2OS cells, in which the expression of specific TLS DNA
polymerases was knocked down using siRNA
siRNA Control (%) REV3L (%) POLK (%) POLH (%) POLK +REV3L (%) POLK+POLH (%)
Nucleotide inserted opposite BP-G Number of isolates
C 127 (74.3) 52 (36.1) 76 (68) 65(69.9) 55 (42.3) 83 (60.1)
A 11 (6.4) 5 (4.5) 3 (3.2) 2 (1.4)
G 6 (3.5) 2 (1.4) 2 (1.5) 1 (0.7)
T 3 (1.8) 2 (1.4) 2 (1.8) 1 (0.7)
Deletion/insertion 24 (14) 88 (61.1) 29 (25.9) 25 (26.9) 73 (56.2) 51 (37)
Total number 171 (100) 144 (100) 112 (100) 93 (100) 130 (100) 138 (100)
TLS clonesa 147 56 83 68 57 87
Mutagenic TLS (%)b 13.6 7.1 8.4 4.4 3.5 4.6
P¼ 0.2c P¼ 0.2c P¼ 0.042c P¼ 0.037c P¼ 0.03c
Nucleotide inserted opposite cisPt-GG Number of isolates
CC 98 (78.4) 53 (53) 60 (87) 59 (70.2) 50 (58.1) 44 (77.2)
AC 15 (12) 9 (9) 2 (2.9) 7 (8.3) 4 (4.7) 1 (1.8)
TC 6 (4.8) 3 (3.6)
CT 1 (0.8)
CA 2 (2.3)
Deletion/insertion 5 (4) 38 (38) 7 (10.1) 15 (17.9) 30 (34.9) 12 (21.1)
Total isolates 125 (100) 100 (100) 69 (100) 84 (100) 86 (100) 57 (100)
TLS clonesa 120 62 62 69 56 45
Mutagenic TLS (%)b 18.3 14.5 3.2 14.5 10.7 2.2
P¼0.006c P¼ 0.01c
aThe number of clones, excluding clones having large deletions or insertions.
bThe percentage of mutagenic TLS is the fraction of events other than insertion of C opposite BP-G, or CC opposite cisPt-GG out of the total
number of TLS events.
cP-value is given compared with the results obtained with cells transfected with control siRNA. Analysis was performed using the w2 test.
P-values that reached statistical significance are in bold face type.
U2OS cells were transfected with the indicated siRNAs. After incubation of 72 h, the plasmid mixtures containing the gap-lesion plasmid
GP-BP-G1 or GP-cisPt-GG (kanR), along with the control gapped plasmid GP20 (cmR) and the carrier plasmid were introduced into the cells.
Following incubation of 8 h to allow TLS, the DNA was extracted and used to transform a recA E. coli indicator strain. GP-BP-G1 or GP-cisPt-GG
(kanR) descendents were extracted from kanR colonies and subjected to DNA sequence analysis. Deletions and insertions are taken as non-TLS
events.
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are bypassed by polz, at most 18% are bypassed by other
polymerases, without the involvement of polz. However, polk
is involved in bypass of 57% of the BP-G adducts. This means
that at least 39% of the lesions are bypassed in a TLS
pathway that involves the action of both polk and polz.
TLS became 3.1-fold less mutagenic (P¼ 0.042) when POLH
was knocked down (Figure 4B; Table I), whereas when POLK
was knocked down, there was a 1.9-fold decrease in muta-
genic TLS, but it did not reach statistical significance (P¼ 0.2;
Table I). However, the fraction of deletions and insertions
Figure 4 Polk and polz operate in the same TLS pathway to bypass BP-G in human cells. (A) Relative TLS extent across BP-G in U2OS cells in
which the expression of specific TLS DNA polymerases was knocked down. The experiments were performed as described in the legend of
Figure 3D, and the detailed data are presented in Supplementary Table 22s. TLS extents were given as percentage relative to TLS assayed with
control siRNA, which was 10.9±1.1% (see Supplementary Table 22s). (B) Relative mutagenic TLS across BP-G based on DNA sequence
information of plasmids isolated from colonies obtained in the experiments described in (A). The detailed data are presented in Table I.
Mutagenic TLS, namely the fraction of nucleotides other than C inserted opposite BP-G, was calculated out of all TLS events, and presented
relative to the mutagenic TLS in cells transfected with control siRNA (which was 13.6%; see Table I). (C) RT–PCR of RNA extracted from
human U2OS cells transiently transfected with the indicated siRNA. (D) RT–PCR of POLH and REV3L mRNAs (top) and an immunoblot with
antibodies against polZ (bottom) performed with RNA and protein extracts prepared from U2OS cells transfected with the indicated siRNAs.
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increased from 14 to 25.9% (P¼ 0.012; Table I), and a similar
increase was observed when POLH was knocked down
(Table I). Consistently, when both POLH and POLK were
knocked down, the effect was similar to knocking down
POLH alone, suggesting that polZ is responsible for the
majority of error-prone TLS across BP-G (Table I). Knocking
down both POLK and REV3L decreased mutagenic TLS across
BP-G by 3.9-fold (Figure 4B; Table I; P¼ 0.037).
Polf cooperates with polg and polj in error-free
and error-prone TLS, respectively, across cisPt-GG
in human cells
The question arises whether lesions additional to BP-G are
bypassed by the two-polymerase mechanism. We chose to
address this question by analysing TLS across the adduct
cisPt-GG using the siRNA-based epistasis approach. This
lesion was chosen because there is evidence that polZ
(Bassett et al, 2004) and REV3L (Wu et al, 2004; Zander
and Bemark, 2004) are involved in its bypass; however, as
these were experiments performed with different cells and
under different conditions it was unknown whether the two
operate in the same pathway.
Analysis of TLS across cisPt-GG in cells in which the
expression of POLH was knocked down caused a 53%
reduction in TLS, whereas knocking down of REV3L caused
an 82% decrease (Figure 5A; Supplementary Table 23s). A
similar drastic reduction in TLS (80%) was observed when
both POLH and REV3L were knocked down. Surprisingly,
knocking down the expression of POLK, not known to be
involved in TLS across cisPt-GG, caused a 34% decrease, and
consistently, knocking down both POLK and POLH caused a
78% reduction in TLS, similar to the effect caused by knock-
ing down REV3L alone (Figure 5A; Supplementary Table 23s).
Thus, at least 82% of the cisPt-GG lesions are bypassed by
polz, and a similar fraction is bypassed by polZ and polk
combined. Taken together with the other data, this suggests
that TLS across cisPt-GG can occur by at least two reactions,
each involving two polymerases: one involving polZ and
polz, and the other involving polk and polz. DNA sequence
analysis revealed that the mutagenic TLS decreased by 5.7-
fold when POLK was knocked down (Table I). When POLH
was knocked down mutagenic TLS remained unchanged but
the fraction of deletions/insertions increased 4.5-fold
(Po0.001; Table I). Knocking down both POLH and POLK
caused both a decrease in mutagenic TLS and an increase in
deletions/insertions (Figure 5B; Table I). Taken together,
these results suggest that polz cooperates with polZ to carry
out error-free TLS, and with polk to carry out error-prone TLS
across cisPt-GG.
POLK affects cell viability in response to cisplatin
in human XPA cells in which the expression of POLH
was knocked down
To examine whether the unexpected involvement of POLK in
TLS across the cisPt-GG adduct is relevant to chromosomal
TLS, we examined the viability of XPA cells treated with
cisplatin. These cells are deficient in nucleotide excision
repair, and therefore cell viability in response to cisplatin
was expected to be more dependent on DNA damage toler-
ance mechanisms such as TLS. As can be seen in Figure 5C,
cell viability was reduced by 40% in cisplatin-treated (1 mM)
cells in which the expression of POLH was knocked down
compared with cells transfected with a control siRNA, con-
sistent with the known involvement of POLH in TLS across
cisplatin-DNA adducts. Knocking down POLK alone had
essentially no effect; however, when both POLH and POLK
were knocked down, the viability of cisplatin-treated cells
decreased by 70% (3.3-fold decrease; Figure 5C). At a lower
cisplatin concentration (0.5 mM) knocking down POLH or
POLK alone had no effect on viability, but knocking down
both caused a 48% decrease in cell viability (Figure 5C).
Although this does not provide direct proof for the involve-
ment of POLK in chromosomal TLS across cisplatin adducts,
it is consistent with such a possibility, further strengthening
the conclusion from our gap-lesion plasmid assay.
Figure 5 Polz cooperates with polZ and polk in error-free and
error-prone TLS, respectively, across cisPt-GG in human cells.
(A) Relative extent of TLS across cisPt-GG in U2OS cells in which
the expression of specific TLS DNA polymerases was knocked
down. The experiments were performed as described in the legend
of Figure 4A, and the detailed data are presented in Supplementary
Table 23s. (B) Relative mutagenic TLS across cisPt-GG based on
DNA sequence information of plasmids isolated from colonies
obtained in the experiments described in (A). The detailed data
are presented in Table I. Mutagenic TLS, namely the fraction of
nucleotides other than CC inserted opposite cisPt-GG, was calcu-
lated out of all TLS events, and presented relative to the mutagenic
TLS in cells transfected with control siRNA (which was 18.3%; see
Table I). (C) Cisplatin sensitivity of XPA cells in which the expres-
sion of POLH and POLK was knocked down. XP12RO cells were
transfected with the indicated siRNAs, after which they were treated
with 0.5 or 1mM cisplatin. Results are given relative to the viability
of cells transfected with control siRNA (77 and 55% for 0.5 and
1 mM cisplatin, respectively). Cell viability was measured using a
luminescence-based assay for measuring ATP.
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Discussion
A pivotal role for polf in both error-prone and error-free
TLS in mammalian cells
Our results suggest that TLS operates in three distinct pathways:
a very fast and accurate pathway that involves polZ, a delayed,
accurate and fast TLS pathway, which involves two poly-
merases, including polz, and a slow and highly mutagenic
pathway, which involves polz (Figure 6). Out of the seven
DNA lesions examined, only TT CPD was bypassed in the
very fast and accurate TLS pathway (Figure 1). It is well
established that polZ is involved in TLS across TT CPD
(Maher et al, 1976; Johnson et al, 1999a; Masutani et al,
1999), including in our assay (Hendel et al, 2008). The TT
CPD was the only lesion analysed, the bypass of which did not
require polz. In fact, it may not need any DNA polymerase
except for polZ, given its superior catalytic properties and its
relatively high fidelity when replicating across a TT CPD
(Johnson et al, 2000b; Masutani et al, 2000; McCulloch et al,
2004). These properties are manifested during replication of UV-
irradiated cells in culture, as indicated by their ability to divide
in the presence of CPD (Spivak and Hanawalt, 1992). Given the
evolutionary importance of UV light, the pathway of fast and
accurate bypass of TT CPD by polZ may represent a special case,
which is unique for CPD.
Mammalian cells contain no less than 15 DNA poly-
merases, yet polz stands out as a key TLS polymerase
involved in TLS across all lesions examined, except the TT
CPD. Moreover, unlike in the S. cerevisiae paradigm, where
polz appears to be involved only in error-prone TLS, in
mammals it is involved in both error-free and error-prone
TLS. Although this is somewhat surprising, because the
apparent lack of backup to the function of polz introduces
vulnerability into the TLS system, it may explain why polz is
the only TLS polymerase that is essential in mice
(Wittschieben et al, 2006; Gan et al, 2008). One possibility
for having a common enzyme in several pathways is regula-
tion; however, this possibility remains to be explored.
Discrete two-polymerase combinations define error-free
and error-prone TLS across BP-G and cisPt-GG
TLS across two of the lesions studied, BP-G and cisPt-GG
involved the action of at least three polymerases: polk, polZ,
and polz. Taking into account the properties of the human
polk and polZ, and the putative polz (based on the
S. cerevisiae polz; Johnson et al, 2000a), the most likely ex-
planation is that these lesions are bypassed in a two-polymerase
mechanism: In the first step, polk or polZ inserts a nucleotide
opposite BP-G or cisPt-GG, and in the second step, polz
performs the extension past each of the two lesions
(Figure 6). Error-prone TLS across BP-G involves primarily
polZ, as indicated by the decreased mutagenicity of TLS
when POLH expression was knocked down (Table I). In the
case of cisPt-GG, both polZ and polk are involved in its
bypass, and knocking down both causes a reduction of TLS
similar to that caused by knocking down polz. Interestingly,
polZ and polz together carry out largely error-free TLS,
whereas polk and polz lead to a largely error-prone outcome
of TLS across cisPt-GG. The involvement of polk in TLS
across cisPt-GG was unexpected, as purified recombinant
polk was reported to be unable to bypass a cisPt-GG lesion
(Ohashi et al, 2000; Gerlach et al, 2001). The in vivo activity
may be enabled by interaction with auxiliary proteins. Its
relevance to chromosomal TLS is indicated by the decreased
viability of cisplatin-treated XPA cells in which both POLK
and POLH were knocked down, compared with cells in which
only POLH was knocked down (Figure 5C). Our results
support the two-polymerase model for TLS proposed by
L Prakash and S Prakash (Johnson et al, 2000a) based on
experiments with purified proteins. To the best of our knowl-
edge, the data presented here provide the first evidence for a
two-polymerase TLS mechanism in living mammalian cells.
The fact that BP-G requires two polymerases for bypass in
mammalian cells is surprising, because purified polk com-
pletely bypasses BP-G (Zhang et al, 2000; Avkin et al, 2004).
Moreover, human purified polk was shown to be a general
extender (Washington et al, 2002), similar to the yeast polz.
Thus, under our conditions, the extender capacity of polk is
not sufficient to catalyse efficient TLS across BP-G, and polz
is needed. The need for polz in TLS across cisPt-GG is
similarly surprising. Human purified polZ was shown to
bypass cisPt-GG (Vaisman et al, 2000), yet polz is needed
for efficient TLS across it. A possible explanation might be
that although polZ is efficient and accurate in incorporating a
nucleotide opposite the 30 G of the cisplatin-GG lesion, it is
inhibited at the 50 G (Alt et al, 2007).
Figure 6 A model for three pathways of TLS in mammalian cells. TLS across a TT CPD is rapid and accurate, and occurs most likely by a single
DNA polymerase, polZ (A). TLS across cisPt-GG and BP-G occurs by a two-polymerase TLS pathway, which is rapid and accurate but delayed,
and involves a combination of polz with either polZ or polk (B). TLS across an AP site occurs by a slow and highly mutagenic TLS pathway,
which involves polz, and most likely an additional DNA polymerase (C). See text for details.
Accurate and mutagenic two-polymerase TLS with polf
S Shachar et al
The EMBO Journal VOL 28 | NO 4 | 2009 &2009 European Molecular Biology Organization390
Our results are consistent with previous reports demon-
strating the involvement of polk in chromosomal mutation
induced by BP in mouse (Ogi et al, 2002; Bi et al, 2005)
and of polz in human cells (Li et al, 2002). Similarly,
sensitivity to and mutagenesis by cisplatin in human
cells involves polZ and polz (Bassett et al, 2004; Wu et al,
2004). It should be emphasized that the chromosomal
studies assayed survival and mutagenesis, not TLS, and
therefore accurate TLS, which accounts for most TLS events
across BP-G and cisPt-GG, could not be scored. Moreover,
any effects observed in assaying chromosomal mutagenesis
may have been caused by a combination of effects
on excision repair, recombination repair, and checkpoint
activation.
Slow and mutagenic polf-dependent TLS across a wide
variety of DNA lesions
Three lesions, TT 6-4PP, 4-OHEN-C, and AP site were by-
passed in a slow and highly mutagenic fashion (up to 80%
errors). The inferior TLS across these lesions compared with
TLS across TT CPD, BP-G, and cisPt-GG may be due to a
combination of the severity of the former, namely the large
deviation from the normal structure that they force on the
DNA, and the lack of an appropriate specialized DNA poly-
merase. After all, the repertoire of the DNA lesions far
exceeds the number of TLS DNA polymerases. At this
point, we do not know yet whether any other polymerase is
required in this pathway in addition to polz. TLS across the
AP site does not require polZ (Avkin et al, 2002) or polk
(unpublished data), but is aphidicolin-sensitive, consistent
with the involvement of an additional polymerase, perhaps
pold (Avkin et al, 2002). The big diversity of lesions bypassed
by this pathway, including the M12 insert, which represents
an artificial and severe type of DNA damage, suggests that
this TLS pathway functions as a general-specificity TLS path-
way, in charge of dealing with a variety of DNA lesions,
including novel ones. Its mutagenic nature indicates that
lesions are bypassed at the cost of increased mutation, a
price that is apparently not too high given the alternative of a
stuck replication fork or persistent gap, which might be
broken leading to DSB. The slow rate of this pathway may
reflect not only the difficulty of the TLS machinery to deal
with these types of lesions but also a negative regulation to
enable an alternative mechanism to act. Such a mechanism
may involve the Rad5-dependent damage avoidance or
homologous recombination repair, which cannot be detected
in our assay.
Conclusions
The results presented here suggest that TLS operates in
mammalian cells in at least three distinct pathways, of
which two are fast and accurate, and one slow and muta-
genic. Surprisingly, polz is involved in both error-free and
error-prone TLS, making it a key and bottleneck component
of the TLS system in mammalian cells. Moreover, evidence is
presented that discrete two-polymerase combinations with
polz dictate error-prone or error-free TLS across the same
lesion: polk and polz carry out error-free TLS of BP-G, but
error-prone TLS of cisPt-GG, whereas polZ and polz carry out
error-free TLS of cisPt-GG, but error-prone TLS of BP-G. To
the best of our knowledge, this is the first report on the
involvement of mammalian polz in error-free TLS, and the
first evidence for a two-polymerase mechanism in mamma-
lian cells.
Materials and methods
Construction of gapped DNA substrates
The construction of gap-lesion plasmids was described earlier
(Reuven et al, 1999; Avkin et al, 2002, 2006; Maor-Shoshani et al,
2003; Adar and Livneh, 2006; Hendel et al, 2008), and is further
detailed in the Supplementary data, along with the DNA sequences
in the vicinity of the lesions.
In vivo TLS assay
The TLS assay was described earlier (Avkin et al, 2004, 2006).
Briefly, cells were co-transfected with a mixture containing 50 ng of
a gapped-lesion plasmid (kanR), 50 ng of a gapped plasmid without
lesion (GP20-cm, cmR), and 10mg of the carrier plasmid pUC18,
using jetPEI/DNA complexes (Polyplus-transfection, Illkirch,
France). For kinetics experiments, cells were transfected by
electroporation with the NucleofectorTM system (Amaxa GmbH,
Köln, Germany), which enables fast delivery. A similar DNA
mixture was used, except that it contained 4.9mg of the carrier
plasmid pUC18. The gap-filling kinetics of the normalizing plasmid
itself (GP20) was examined by transfecting U2OS cells with a
mixture of GP20 (kanR) and a normalizing covalently closed
plasmid pSA26 (cmR) (Avkin et al, 2002), and found to be
completely filled in less than 30 min (data not shown). The
efficiency of gap repair was calculated by dividing the number of
transformants obtained from the gap-lesion plasmid (number of
colonies on LB-kan plates) by the number of corresponding
transformants obtained with the control gapped plasmid GP20-cm
(number of colonies on LB-cm plates). Plasmids were extracted
from kanR colonies, and the sequence opposite the lesion was
determined by automated DNA sequencing analysis in the
Biological Services Department at the Weizmann Institute. To
obtain values of TLS from values of gap repair, the latter were
multiplied by the percentage of TLS events out of the total events, as
determined by the DNA sequence analysis.
Knocking down of DNA polymerase genes
The expression of specific DNA polymerase genes was knocked
down in U2OS cells by transfection with specific siRNA pools
(50 nM) in 6-cm plates. All siRNAs were from Dharmacon: POLK
SMARTpool M-021038, REV3L SMARTpool M-006302, POLH
SMARTpool M-006454, and siControl non-targeting pool D-
001206-14. Transfection was carried out using 12 ml/plate HiPerFect
(Qiagen). After 48 h in culture with siRNA, cells were split 1:3, and
after additional 24 h the TLS assay was conducted as described
above.
Measurement of viability of cisplatin-treated human cells
Human XP12RO (SV40-tranformed XPA) cells were reverse-trans-
fected with on-target plus siRNA (Dharmacon) in a 96-well plate
format, and after 24 h the medium was replaced with a fresh
medium containing 0.5 or 1 mM cisplatin. Viability was measured
72 h later, using CellTiter-Glo luminescent cell viability assay, which
measures ATP levels (Promega).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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